The biology and treatment of plasmablastic lymphoma

Blood

Volumn 125, Issue 15, 2015, Pages 2323-2330

  Castillo, Jorge J ^a   Bibas, Michele ^b   Miranda, Roberto N ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

CLINICAL FEATURE; GERMINAL CENTER; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOPHENOTYPING; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); ANIMAL; B LYMPHOCYTE; COMPLICATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HIV INFECTIONS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84927547047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-567479     Document Type: Review

References (71)

1. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413-1420.
2. Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:256-257.
3. Castillo JJ, Furman M, Beltrán BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270-5277.
4. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28(6):736-747.
5. Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875-886.
6. Schommers P, Wyen C, Hentrich M, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS. 2013;27(5):842-845.
7. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004;15(11):1673-1679.
8. Bibas M, Castillo JJ. Current knowledge on HIV-associated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064.
9. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002;33(4):392-404.
10. Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011;35(12):1571-1577.
11. Cattaneo C, Facchetti F, Re A, et al. Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. Leuk Lymphoma. 2005;46(1):77-81.
12. Natkunam Y. The biology of the germinal center. Hematology Am Soc Hematol Educ Program. 2007;210-215.
13. Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev. 2012;247(1):11-23.
14. Spender LC, Inman GJ. Inhibition of germinal centre apoptotic programmes by Epstein-Barr virus. Adv Hematol. 2011;2011:829525.
15. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17(6):1700-1709.
16. Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYCinduced lymphomagenesis. Oncogene. 2009;28(11):1471-1476.
17. Lavorgna A, Harhaj EW. EBV LMP1: New and shared pathways to NF-κB activation. Proc Natl Acad Sci USA. 2012;109(7):2188-2189.
18. Khanim F, Dawson C, Meseda CA, et al. BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. J Gen Virol. 1997;78(Pt 11):2987-2999.
19. Cooper A, Johannsen E, Maruo S, et al. EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J Virol. 2003;77(2):999-1010.
20. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21):6479-6483.
21. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer. 2003;36(3):211-223.
22. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013; 122(24):3884-3891.
23. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149(4):484-497.
24. Simonitsch-Klupp I, Hauser I, Ott G, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 2004;18(1):146-155.
25. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Reports. 2014;6(1):130-140.
26. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18(6):806-815.
27. Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132(4):597-605.
28. Valera A, Balagué O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686-1694.
29. Chang CC, Zhou X, Taylor JJ, et al. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009;2:47.
30. Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16(1):87-96.
31. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328-340.
32. Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008:260-261.
33. Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011;136(2):183-194.
34. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27(25):4211-4216.
35. Delsol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:254-255.
36. Chan JK, Aozasa K, Gaulard P. DLBCL associated with chronic inflammation. In: Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:245-246.
37. Aguilar C, Beltran B, Quiñones P, et al. Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus? Cardiovasc Pathol. 2015;24(1):60-64.
38. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804-809.
39. Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11(2):185-189.
40. Noy A, Chadburn A, Lensing SY. Moore P. Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC) [abstract]. Blood. 2013;122(21). Abstract 1801.
41. Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. Leuk Lymphoma. 2015;56(1):267-279.
42. Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-2053.
43. [No authors listed]. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
44. Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293-299.
45. Armstrong R, Bradrick J, Liu YC. Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. J Oral Maxillofac Surg. 2007;65(7):1361-1364.
46. Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma. 2002;43(2):423-426.
47. García-Noblejas A, Velasco A, Cannata-Ortiz J, Arranz R. Spontaneous regression of immunodeficiency associated plasmablastic lymphoma related to methotrexate after decrease of dosage [in Spanish]. Med Clin (Barc). 2013;140(12):569-570.
48. Guidelines Version NCCN. 4.2014. AIDS-Related B-Cell Lymphomas. http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. Accessed September 18, 2014.
49. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-2724.
50. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-934.
51. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492-1499.
52. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118(16):3977-3983.
53. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non- Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262.
54. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20(12):1877-1884.
55. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
56. Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010;28(34):e704-e708.
57. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009;82(6):490-492.
58. Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014;14(5):e145-e150.
59. Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haematolymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013;31(3):164-166.
60. Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(5):E43-E46.
61. Saba NS, Dang D, Saba J, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36(5):287-291.
62. Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93(1):77-80.
63. Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma [published online ahead of print January 22, 2015. Br J Haematol.
64. Folk GS, Abbondanzo SL, Childers EL, Foss RD. Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol. 2006;10(1):8-12.
65. Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013;31(12):e197-e199.
66. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571-2578.
67. Castillo JJ, Reagan JL, Bishop KD, Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol. 2014;165(3):300-315.
68. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2(10):740-749.
69. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell. 2003;112(2):193-205.
70. Rahl PB, Lin CY, Seila AC, et al. c-Myc regulates transcriptional pause release. Cell. 2010;141(3):432-445.
71. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.